This inventor holds 1 USPTO granted patent. Top assignee: Incyte Corporation. Active years: 2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2010
Title: Argyrios G. Arvantis: Patent Inventor in Pharmaceutical Research
Introduction
Argyrios G. Arvantis is an inventor associated with Incyte Corporation and based in Kennett Square, Pennsylvania. His patent work concerns active metabolites of a Janus kinase inhibitor and their potential therapeutic applications. The available information identifies 1 patent associated with him.
Latest Patents
Arvantis is named on the patent “Metabolites of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile.” The invention describes active metabolites that modulate Janus kinase activity. It identifies potential uses in treating conditions related to Janus kinase activity, including immune-related diseases, skin disorders, myeloid proliferative disorders, and cancer.
Career Highlights
Arvantis’s listed patent reflects work in pharmaceutical research focused on Janus kinase pathways. These pathways are relevant to a range of diseases, making the study of compounds that modulate their activity an important area of therapeutic development. The available information associates his work with Incyte Corporation.
Collaborations
The patent’s listed collaborators include James David Rodgers and Jack Guoen Shi. Their shared work addresses active metabolites and their potential role in modulating Janus kinase activity.
Conclusion
Argyrios G. Arvantis’s patent contribution centers on metabolites of a Janus kinase inhibitor and their potential applications across several disease areas.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile